An online pharmacy is calling for U.S. regulators to recall batches of the metformin diabetes medicine made by nearly a dozen companies after its tests found excessive amounts of a possible carcinogen, the same substance that has already prompted widespread recalls of blood pressure and heartburn pills. Metformin is used to control high blood sugar levels in people with Type 2 diabetes.

In a petition filed with the Food and Drug Administration, Valisure stated that independent laboratory testing detected NDMA above the daily acceptable intake level in 16 batches of the diabetes treatment made by 11 different manufacturers. And several batches contained more than 10 times the acceptable limit, with significant variations seen in batches made in some cases by the same company.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy